A biotech betting that Parkinson's begins below the brain
For more than a century, the fight against neurodegenerative disease has been fought almost entirely inside the skull. Vertero Therapeutics, a small clinical-stage company headquartered at 400 Tradecenter Drive in Woburn, Massachusetts, is running a different experiment. Its wager is that some of the earliest, most actionable drivers of diseases like Parkinson's are not in the brain at all - they are in the gut.
The idea is not marketing. Neurologists have long noted that many people with Parkinson's disease experience constipation and slowed gut motility years before a tremor ever appears. Studies have repeatedly documented distinct changes in the gut microbiome of Parkinson's patients. Vertero was built to take that clue seriously and turn it into a drug.
The company was founded in 2016 - then under the name Axial Therapeutics - by Sarkis K. Mazmanian, a Caltech microbiologist whose research helped map the biological conversation between the gut and the brain. In October 2025 the company rebranded as Vertero Therapeutics, a shift that coincided with a $20 million Series D financing and a sharpened focus on peripheral drivers of neurodegeneration.
"Our unique expertise is in the interplay between the brain and the peripheral nervous system."
- A. Stewart Campbell, PhD, Chief Executive OfficerOral drugs, aimed at the periphery
Vertero develops oral small-molecule therapeutics for neurodegenerative diseases. Where conventional programs try to design molecules that cross the blood-brain barrier and act inside the central nervous system, Vertero deliberately does the opposite: its lead drug is engineered to stay in the gut, acting on a target that sits at the very start of the disease chain.
The company describes its edge as "a unique combination of unorthodox thinking and integrated expertise." Its team pulls together microbiology, neuroscience and drug development to move past correlation and isolate causative drivers - the difference between noticing that Parkinson's patients have unusual gut biology and knowing exactly which molecule to drug.
That focus produces a very specific kind of ambition. Vertero is not promising to reverse Parkinson's or cure it outright. Its stated goal is more measured and, arguably, more honest: to delay onset, slow progression, and preserve patients' quality of life for longer - buying good years before symptom-driven treatment becomes necessary.
Beyond its Parkinson's work, the company has a second, earlier-stage program targeting bile acid dysregulation for undisclosed indications, and it sees potential to extend the peripheral-targeting approach to Lewy body dementia and Alzheimer's disease.
Following the trail from gut to brain
Vertero's lead candidate, VT-5006, is a first-in-class, gut-selective oral small molecule. It targets CsgA, a microbial protein expressed when certain gut bacteria bind to the intestinal wall. Here is the chain of events the drug is designed to interrupt:
Bacteria bind the gut
Gut bacteria attach to the intestinal wall and express the protein CsgA.
CsgA drives aggregation
Found in over half of PD patients, CsgA seeds protein misfolding and aggregation.
Spread & inflammation
Aggregates propagate toward the brain and fuel neuroinflammation.
VT-5006 intervenes
A localized oral drug for PD patients with confirmed gut CsgA - disrupting pathology at its source.
Mechanism as described on Vertero's published materials. VT-5006 is investigational and has not been approved by any regulatory authority.
Precision without genetics
As a pre-commercial company, Vertero has no customers in the ordinary sense - it has beneficiaries and stakeholders. The ultimate beneficiaries are people living with Parkinson's disease and, potentially, other neurodegenerative conditions, along with the neurologists who treat them. Its immediate stakeholders are investors, disease foundations, and the patients who join its clinical trials.
The problem Vertero attacks is stark. Parkinson's is progressive and, today, managed largely by treating symptoms once they arrive. There is a deep unmet need for therapies that intervene earlier, upstream of the damage.
What makes Vertero's approach notable is how it selects patients. Rather than sorting by genetics, VT-5006 is intended specifically for PD patients with confirmed CsgA in the gut - a biological, testable marker. It is precision medicine addressed to biology's actual location rather than an inherited code.
That specificity is a feature, not a limitation. Designing a drug for the subset of patients whose disease shows the target it treats is exactly the kind of matching modern drug development aims for.
Patient capital for a long problem
Vertero has raised capital across several equity rounds since 2016, backed by specialist life-science investors and, notably, patient-advocacy funding from The Michael J. Fox Foundation for Parkinson's Research - which awarded the company research grants in 2020 and 2023.
Series B was undisclosed. Bars are scaled to disclosed round sizes for illustration. Investors across rounds include Longwood Fund, Seventure Partners, Domain Associates, Taiho Ventures, OneVentures, UTokyo Innovation Platform, Autism Impact Fund and Corundum Systems Biology.
A contrarian corner of neuroscience
The neurodegeneration field is crowded with brain-first programs, many chasing alpha-synuclein and neuroinflammation directly in the central nervous system - and littered with high-profile failures. Vertero's differentiation is its direction of attack: it treats the disease as a conversation between the gut and the brain and intervenes on the peripheral side of that dialogue.
Its competitive neighbors are other microbiome and gut-brain-axis companies and gut-targeted small-molecule developers, alongside the broader universe of conventional Parkinson's drug developers. What sets Vertero apart within that market is the combination of a named molecular target (CsgA), a testable patient-selection marker, and roots in rigorous Caltech microbiome science.
"Vertero's novel approach of identifying and treating upstream peripheral molecular targets has strong potential to transform the way Parkinson's disease is treated."
- Kalpana Merchant, PhD, Scientific Advisory Board ChairTwo programs, one thesis
VT-5006
A first-in-class, gut-selective oral small molecule for Parkinson's disease. Targets the bacterial protein CsgA to delay onset and slow progression. Entering Phase 1 clinical trials.
Bile Acid Program
An early-stage asset targeting bile acid dysregulation for undisclosed neurodegenerative indications.
Beyond Parkinson's
The peripheral-targeting platform shows potential to extend to Lewy body dementia and Alzheimer's disease.
People who know the terrain
Vertero pairs a lean operating team with an unusually decorated bench of advisors. CEO A. Stewart Campbell, PhD, who joined in 2017 and took the top job in February 2021, brings more than 30 years of experience building teams that discover and develop novel therapeutics. In December 2025 the company assembled a Scientific Advisory Board of globally recognized Parkinson's and neuroscience leaders.
Scientific Advisory Board also includes Bastiaan R. Bloem, MD, PhD; Anthony Schapira, MD; and David G. Standaert, MD, PhD.
From lab clue to clinic
Founded as Axial Therapeutics
Caltech microbiologist Sarkis Mazmanian launches the company on the gut-brain connection with a $19.15M Series A.
Stewart Campbell joins
The future CEO comes aboard and becomes central to the company's growth and strategy.
Michael J. Fox Foundation grant
A research grant funds an enteric nervous system model for testing Parkinson's therapeutics.
CEO named & $37.25M Series C
Campbell is appointed CEO in February; OneVentures and UTokyo IPC lead a Series C in October.
Second MJFF grant
Additional Fox Foundation funding advances the gut-targeted Parkinson's candidate.
Rebrand to Vertero, Series D & Phase 1
The company becomes Vertero, raises $20M, prepares VT-5006 for Phase 1, and names a Scientific Advisory Board and new CBO.
What people ask about Vertero
What does Vertero Therapeutics do?
Vertero is a clinical-stage biotech developing oral small-molecule drugs for neurodegenerative diseases by targeting causative drivers in the body's periphery, mainly the gut, rather than only the brain.
Was Vertero previously called something else?
Yes. Vertero Therapeutics was formerly Axial Therapeutics (and earlier Axial Biotherapeutics); it rebranded as Vertero in October 2025.
What is VT-5006?
VT-5006 is Vertero's lead candidate: a gut-selective oral small molecule for Parkinson's disease that targets the bacterial protein CsgA, aiming to delay onset and slow progression. It is entering Phase 1 trials.
Who founded and leads Vertero?
It was founded in 2016 by Caltech microbiologist Sarkis K. Mazmanian. A. Stewart Campbell, PhD, has been CEO since February 2021.
How much funding has Vertero raised?
The company has raised tens of millions across Series A through D rounds - including a $37.25M Series C in 2021 and a $20M Series D in 2025 - plus research grants from The Michael J. Fox Foundation.
Interviews & the science, in motion
Search these to see the gut-brain thesis explained by the people building on it:
Links, news & social
Sources: Vertero Therapeutics official site; BioSpace; GlobeNewswire; Microbiome Times; Longwood Fund; Parkinson's News Today; VCNewsDaily; OneVentures; PR Newswire. Figures are as publicly reported and may be approximate.